Transcatheter Tricuspid Valve Replacement After Failed Transcatheter Annuloplasty and Edge-to-Edge Repair.

ABSTRACT:

Background

The EVOQUE transcatheter tricuspid heart valve (Edwards Lifesciences) is approved for high-risk patients with severe tricuspid regurgitation (TR). This report describes the first EVOQUE implantation after failed percutaneous tricuspid annuloplasty and edge-to-edge repair.

Case summary

An 80-year-old man with atrial fibrillation underwent percutaneous annuloplasty with a Cardioband (Edwards Lifesciences) for torrential TR. Initially improved, TR recurred within a year, accompanied by severe mitral regurgitation. The patient underwent mitral and tricuspid edge-to-edge repairs, improving symptoms to NYHA functional class II, but TR persisted because of a large coaptation gap. Three years later, TR worsened as a result of single-leaflet device attachment. After multid

SUBMITTER: Toggweiler S 

PROVIDER: S-EPMC12441407 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature